Retatrutide Shows 28% Weight Loss in Phase 3 Trial
-
By
-
Kathryn Wighton
-
May 21, 2026
-
2 min
By
Kathryn Wighton
May 21, 2026
Combined rheumatoid factor and anticitrullinated protein antibody status appeared to modify the association between baseline rheumatoid arthritis disease activity and subsequent cardiovascular events in an international observational cohort.
July 15, 2026
A nationwide Swedish cohort found a higher relative risk of anterior ischemic optic neuropathy among GLP-1 receptor agonist users, but the overall risks were low.
July 14, 2026
In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.
July 13, 2026